Search for: "Janssen v. Janssen"
Results 301 - 320
of 385
Sorted by Relevance
|
Sort by Date
3 Mar 2010, 5:05 am
(IP Osgoode) Australia: University of Western Australia’s application to appeal FCAFC’s decision in University of Western Australia v Gray fails (IP Whiteboard) Colombia/EU/Peru: Tough IP health provisions in Europe’s Colombia/Peru trade deal (IP Watch) (IP tango) EU: Something more about Swiss type claims: G02/08 (SiNApSE) (SiNApSE) US: Pharmaceutical patent settlements – and what about patients? [read post]
17 Feb 2010, 5:10 am
(Patent Docs) Razadyne (Galantamine) / Strattera (Atomoxetine) – US: Walking the enablement/non-obviousness tightrope: Janssen Pharmaceutica N.V. v. [read post]
20 Mar 2009, 2:05 am
Janssen Pharmaceutica, Inc., 2006 WL 3665417, at *4 (S.D. [read post]
22 Apr 2016, 12:51 pm
Buckman Co. v. [read post]
31 Dec 2014, 5:00 am
Janssen Pharmaceutica, Inc., 144 So.3d 898 (La. 2014). [read post]
2 Nov 2011, 2:00 am
Novartis Vaccines & Diagnostics (Pharma Patents) US: CAFC Affirms district court de novo review in section 146 action: Streck v. [read post]
21 Mar 2014, 11:38 am
When it comes to yesterday’s decision from the Arkansas Supreme Court in Ortho-McNeil-Janssen Pharms., Inc. v. [read post]
2 Feb 2010, 7:28 am
N.J. 1981) (label change); Janssen Pharmaceutica, Inc. v. [read post]
13 Jul 2017, 8:47 am
The judgment comes as a surprise, as the previously established UK case law had over time firmly done away with the idea of ‘pith and marrow’ infringement, culminating in the seminal House of Lords judgment in Kirin-Amgen v Hoechst Marion Roussel [2004] UKHL 46. [read post]
13 Jul 2017, 8:47 am
The judgment comes as a surprise, as the previously established UK case law had over time firmly done away with the idea of ‘pith and marrow’ infringement, culminating in the seminal House of Lords judgment in Kirin-Amgen v Hoechst Marion Roussel [2004] UKHL 46. [read post]
7 Jan 2010, 10:36 am
Boyd v. [read post]
10 Mar 2014, 11:31 am
Ortho-McNeil-Janssen Pharmaceuticals, 2013 WL 2917651, at *28 (Pa. [read post]
15 Jul 2009, 5:15 am
IPAB rejects Novartis’ patent application for Glivec (Intellectual Property Watch) Lescol (Fluvastatin) – Netherlands: No interim relief pending appeal against invalidity, rules District Court of The Hague: Novartis v Mylan and Actavis (PatLit) Levaquin (Levoflaxacin) – Canada: FCA holds generics raising allegations similar to those of previous generics allowed their day in court: Apotex v Janssen-Ortho (Global IP Watch) Lexapro (Escitalopram)… [read post]
17 May 2021, 4:17 am
Janssen Pharmaceutica NV & Another 1998 BIP 264. [read post]
23 Mar 2024, 5:29 pm
While the Court of Appeal in John v. [read post]
10 Apr 2014, 11:58 am
Janssen Pharmaceuticals, Inc., 2014 WL 1335511 (Pa. [read post]
21 Dec 2012, 11:41 am
Janssen Pharmaceutical, Inc., ___ So.3d___, 2012 WL 3761900 (La. [read post]
6 Jun 2017, 12:53 am
Founder v. [read post]
24 Apr 2013, 8:31 am
Food & Drug Law Institute Annual Conference Top 20 Cases in Food & Drug Law in 2012 and Cases to Watch in 2013 Bill Janssen, Charleston School of Law: Weddle v. [read post]
29 Aug 2016, 1:19 pm
Risperdal is the name Janssen patented and used when marketing the product. [read post]
